Issues
-
Cover Image
Cover Image
Individuals harboring inherited heterozygous mutations of the BAP1 gene are predisposed to a spectrum of neoplasms, including malignant mesothelioma. Using genetically engineered mouse models, it was found that inactivating germline Bap1 mutations behave as potent cancer susceptibility alleles, giving rise to a variety of malignant tumor types, including occasional mesotheliomas. However, high penetrance of mesothelioma in Bap1-mutant mice required exposure to asbestos. The image depicts hematoxylin and eosin staining of a spontaneous malignant mesothelioma invading the pancreas of mouse with a germline Bap1 mutation. For details, see article by Kadariya and colleagues on page 2836. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Cancer Research 75th Anniversary Commentaries
Reviews
Integrated Systems and Technologies
Microenvironment and Immunology
TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis
Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies
CSF1 Overexpression Promotes High-Grade Glioma Formation without Impacting the Polarization Status of Glioma-Associated Microglia and Macrophages
IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors
Stromal-Based Signatures for the Classification of Gastric Cancer
Molecular and Cellular Pathobiology
The Prosurvival IKK-Related Kinase IKKϵ Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine
Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma
The Ribonucleic Complex HuR-MALAT1 Represses CD133 Expression and Suppresses Epithelial–Mesenchymal Transition in Breast Cancer
An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression
Therapeutics, Targets, and Chemical Biology
CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1–Dependent IGF-1 Signaling
Natural Product Vibsanin A Induces Differentiation of Myeloid Leukemia Cells through PKC Activation
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells
Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
Tumor and Stem Cell Biology
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.